Entrada Therapeutics (NASDAQ:TRDA) shares maintained a Buy rating and a $20.00 price target from H.C. Wainwright, well below the highest analyst target of $29.00. According to InvestingPro analysis, ...

The Elevate-44-201 study is a global, two-part, randomized, double-blind placebo-controlled phase 1/2 study evaluating the ...

Caregivers of people with Duchenne muscular dystrophy may play an important role in the prevention and management of fat ...

Contrary to prior data, this study shows that neither eosinophils nor STAT6-mediated IL-4/IL-13 signaling contribute ...

Ann Blake, from Godshill, suffers from muscular dystrophy and released a book in 2024 titled  'A Legacy of Love' to share artwork and ...

Johnny Quintana’s life changed at the age of 19 when he was diagnosed with a rare form of muscular dystrophy called ...

Learn more about whether Ionis Pharmaceuticals, Inc. or PTC Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Police are searching for a suspect after a brief standoff involving SWAT on the north side of Indianapolis Tuesday night. A ...

Learn more about whether Avidity Biosciences, Inc. or TG Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

MDA launches 75th Anniversary campaign and premieres new public service announcement (PSA) to mark 75 years of impact in the ...

The data showed reduced difficulties in standing, walking and running that were statistically significant, the company said.